Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.51 |
| ▸ | TERT | O14746 | 3/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | FABP4 | P15090 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.49 |
| ▸ | GMNN | O75496 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4795873 | 1.00 | FAAH (0.53) | FAAHCYP1A2CYP2C19SOAT1KMT2A | |
| SCHEMBL1557690 | 0.89 | CA12 (0.47) | CYP1A2CYP2C19KMT2AMEN1CYP3A4 | |
| SCHEMBL31496780 | 0.89 | CA12 (0.47) | CYP1A2CYP2C19KMT2AMEN1CYP3A4 | |
| SCHEMBL540900 | 0.89 | CA12 (0.47) | CYP1A2CYP2C19KMT2AMEN1CYP3A4 | |
| SCHEMBL6386826 | 0.89 | CA12 (0.47) | CYP1A2CYP2C19KMT2AMEN1CYP3A4 | |
| SCHEMBL4210960 | 0.89 | CA12 (0.47) | CYP1A2CYP2C19KMT2AMEN1CYP3A4 | |
| SCHEMBL3486793 | 0.87 | FAAH (0.54) | FAAHCYP1A2CYP2C19SOAT1KMT2A | |
| Glycine SCHEMBL28998835 | 0.86 | EPHX2 (0.63) | FAAHCYP1A2CYP2C19SOAT1KMT2A | |
| SCHEMBL14759700 | 0.85 | ZDHHC20 (0.47) | FAAHCYP1A2CYP2C19SOAT1KMT2A | |
| SCHEMBL14759698 | 0.85 | ZDHHC20 (0.47) | FAAHCYP1A2CYP2C19SOAT1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100036115-A1 | Novel Compositions for the Delivery of Negatively Charged Molecules | SIRNA THERAPEUTICS, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-7553830-B2 | Compositions for the delivery of negatively charged molecules | SIRNA THERAPEUTICS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1724254-A2 | Novel compositions for the delivery of negatively charged molecules | Sirna Therapeutics, Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1019365-B1 | NOVEL COMPOSITIONS FOR THE DELIVERY OF NEGATIVELY CHARGED MOLECULES | SIRNA THERAPEUTICS INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20050234232-A1 | Novel compositions for the delivery of negatively charged molecules | SIRNA THERAPEUTICS, INC. | 2005-10-20 | — | — | US | disclosed |
| US-20030073640-A1 | Novel compositions for the delivery of negatively charged molecules | RIBOZYME PHARMACEUTICALS, INC. | 2003-04-17 | — | — | US | disclosed |
| US-6395713-B1 | CATIONIC LIPIDCATIONIC LIPID | RIBOZYME PHARMACEUTICALS, INC. | 2002-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036115-A1 | Novel Compositions for the Delivery of Negatively Charged Molecules | PHAX, TARBP1, SNRPE | FAAH 4610/4885CYP1A2 4883/4885CYP2C19 4884/4885 |
| US-20050234232-A1 | Novel compositions for the delivery of negatively charged molecules | PHAX, TARBP1, SNRPE | FAAH 4610/4885CYP1A2 4883/4885CYP2C19 4884/4885 |
| US-20030073640-A1 | Novel compositions for the delivery of negatively charged molecules | PHAX, TARBP1, SNRPE | FAAH 4610/4885CYP1A2 4883/4885CYP2C19 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.